Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

February 22, 2017

Conditions
Thyroid Associated OphthalmopathiesThyroid-Associated Ophthalmopathy
Interventions
DRUG

teprotumumab

DRUG

normal saline

Trial Locations (15)

20122

Fondazione Ca' Granda Ospedale Policlinico Graves GO Center, Milan

30322

Emory University Department of Ophthalmology, Atlanta

38163

Hamilton Eye Institute at University of Tennessee, Memphis

48105

Kellogg Eye Center at University of Michigan, Ann Arbor

52242

University of Iowa Hospitals and Clinics, Department of Ophthalmology, Iowa City

53226

Medical College of Wisconsin, The Eye Institute, Milwaukee

55101

Johannes Gutenberg University Medical Center, Mainz

56100

University of Pisa, Azienda Ospedaliera, Pisa

63110

Washington University Department of Ophthalmology, St Louis

68198

University of Nebraska Medical Center Department of Ophthalmology, Omaha

77005

Eye Wellness Center, Houston

80045

University of Denver, Aurora

90095

Jules Stein Eye Institute at UCLA, Los Angeles

97239

Casey Eye Institute at Oregon Health and Science University, Portland

Unknown

Moorfields Eye Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01868997 - Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease | Biotech Hunter | Biotech Hunter